Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

Night_Owl_Biotech Feb. 4 at 12:49 AM

Commercial-stage oncology focused bio share price changes YTD v the XBI (those with market caps north of $350MM) The XBI is up 4.7% YTD yet only 8 of the 23 bios in this peer group are trading higher YTD. $KURA Investors should take the time to understand KURA's enterprise value (not provided here) & consider their near-term receivables from Kyowa Kirin. $NVCR was trading north of $14 per share as recently as 1/22/26 (well after releasing Q425 sales). We're uncertain why NVCR is off the last 2 weeks. If any NVCR investor can share their insight it would be appreciated. $TLX.X hit a 52-week low. TLX trades for roughly 4X FY25 sales (but at a 62% gross margin) released 3 weeks ago. Look at their share price over the last 5 days. Like NVCR, any insight would be appreciated. $ADCT appears an outlier considering peers. $INCY could buy SNDX for 4.5X FY2029 consensus. In theory, this would be accretive to INCY shareholders. As always, this is not investment advice.

0 · Reply

SuperGreenToday Feb. 3 at 11:13 PM

$INCY Share Price: $100.88 Contract Selected: Sep 18, 2026 $100 Calls Buy Zone: $10.62 – $13.12 Target Zone: $17.00 – $20.78 Potential Upside: 51% ROI Time to Expiration: 226 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 28 at 7:41 PM

$INCY Share Price: $100.22 Contract Selected: Sep 18, 2026 $100 Calls Buy Zone: $10.03 – $12.39 Target Zone: $17.88 – $21.85 Potential Upside: 68% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

stinkroach Jan. 27 at 3:27 PM

$INCY

1 · Reply

JuggernautRaider Jan. 27 at 2:53 PM

$GERN buying shares to complement $CCCC & $SLS in my portfolio. The phase 3 ImpactMF data is a major binary event and will change the second line MF treatment paradigm if positive. $INCY should buy them regardless but if its positive GERN should get back to $5 quickly later this year 🚀

0 · Reply

AdamURAtoFookingNeptune Jan. 23 at 7:52 PM

$EXEL $INCY small trims here

0 · Reply

ProfitFocus_34 Jan. 20 at 4:45 PM

$INCY midcap biotech steady accumulation if data cle

0 · Reply

notreload_ai Jan. 20 at 12:45 PM

Wells Fargo cut $INCY to Equal Weight and lowered its price target to $107. The bank says most upside is already priced in, with no big near-term catalysts, so the stock may trade sideways for now.

0 · Reply

JuggernautRaider Jan. 20 at 2:18 AM

$SNDX $INCY great questions my friend @Night_Owl_Biotech . Syndax’s asking price is likely too high and held back by the risks such as KURA / $SLS / other potential disruptors to the AML space (and God knows those poor patients deserve as much help as they can get). Incyte should have bought Syndax out entirely in 2021 and lately the first partner isn’t always the buyer (e.g., I was at CELG when we signed the first deal with Acceleron for Reblozyl, but $BMY got outbid / outmaneuvered by MRK for their PAH pipeline). At this stage, Incyte can wait for Syndax’s stock too crash… which, with one or two bad quarters or bits of news, it certainly could. Or a bigger pharma like BMS or Novartis with a large hem/onc portfolio will take them out. I don’t own any Syndax - I invest for multibaggers, not 50% premiums - but if you’re a bull there is no reason to not buy dips. It wouldn’t shock me any day to wake up and see SNDX bought out for $30-35 a share. Does @BioRich agree? 🧐

2 · Reply

JuggernautRaider Jan. 19 at 10:21 PM

$INCY I agree 1000% with @Night_Owl_Biotech that Incyte needs to cut some major deals - they’re losing billions in Jakafi revenue soon and their pipeline is not close to ready to replace that. Assuming both $SNDX and $KURA are projected to peak at about $500M in sales, buying them for a nice premium would help mitigate some of the damage. $SLS in the AML maintenance space makes sense as well (they may soon read out game changing data as they wait for the 80th event) ⏰ Incyte’s newish CEO is supposedly a big deal maker but he hasn’t made any yet. Their stock is priced to assume continued growth at about 5x revenues - they’re in for a world of hurt without some smart deals like these in the hematology/oncology space. 🏦 I know @BioCapitalist99 and other Syndax longs would love a nice SNDX buyout. I have friends at both companies- a deal with Incyte makes a ton of sense 👍

2 · Reply

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Jan 27, 2026, 8:00 AM EST - 7 days ago

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

Jan 22, 2026, 2:37 AM EST - 12 days ago

What Investors Should Know Before Buying Incyte

Jan 16, 2026, 1:34 PM EST - 18 days ago

Incyte: Buy For The Turnaround, Stay For The Pipeline

Jan 16, 2026, 8:15 AM EST - 18 days ago

Incyte's Pipeline Potential Signals Massive Upside For Investors

Jan 15, 2026, 11:00 AM EST - 19 days ago

Steven Cress' Top 10 Stocks For 2026

ABX ALL AMD ATI B CIEN CLS

Jan 13, 2026, 6:02 PM EST - 21 days ago

Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

Jan 12, 2026, 2:55 PM EST - 22 days ago

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 2:18 PM EST - 4 weeks ago

Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins

Jan 6, 2026, 1:30 PM EST - 4 weeks ago

Top 10 Stocks For 2026

ALL AMD ATI B CIEN CLS COHR

Jan 5, 2026, 11:59 AM EST - 4 weeks ago

Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Jan 5, 2026, 7:40 AM EST - 4 weeks ago

Incyte's blood cancer therapy meets main goal in late-stage trial

Jan 5, 2026, 7:30 AM EST - 4 weeks ago

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

$Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Dec 22, 2025, 2:44 AM EST - 6 weeks ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Dec 22, 2025, 2:42 AM EST - 6 weeks ago

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Best Defensive Stocks To Balance Tech Sector Volatility

BIP MU RSP VRTX XLK

Dec 18, 2025, 8:00 AM EST - 6 weeks ago

Incyte to Present at Upcoming Investor Conference

$Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Dec 17, 2025, 11:20 AM EST - 6 weeks ago

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Dec 12, 2025, 8:30 AM EST - 7 weeks ago

Incyte Announces Change to its Board of Directors

Dec 9, 2025, 12:59 PM EST - 2 months ago

Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack

NFLX SHAK TMO

Dec 8, 2025, 4:30 PM EST - 2 months ago

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

Dec 7, 2025, 6:23 PM EST - 2 months ago

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript

Dec 7, 2025, 9:30 AM EST - 2 months ago

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Dec 7, 2025, 9:30 AM EST - 2 months ago

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Dec 6, 2025, 9:00 AM EST - 2 months ago

Incyte: Buy At This Inflection Point

Dec 3, 2025, 4:30 PM EST - 2 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 3:13 PM EST - 2 months ago

Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 8:00 AM EST - 2 months ago

Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo

Dec 2, 2025, 2:03 PM EST - 2 months ago

Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 9:15 AM EST - 2 months ago

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

Dec 1, 2025, 8:00 AM EST - 2 months ago

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

Nov 27, 2025, 4:09 AM EST - 2 months ago

Incyte: This Profitable Biotech Trades Like A Melting Iceberg

Nov 27, 2025, 1:11 AM EST - 2 months ago

Incyte: Riding Jakafi, Bracing For Generic Headwinds

Nov 19, 2025, 8:00 AM EST - 2 months ago

Incyte to Present at Upcoming Investor Conferences

Nov 18, 2025, 1:48 PM EST - 2 months ago

Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 4:05 PM EST - 2 months ago

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

PFE PPH VRTX XBI XLV

$Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)$

Nov 17, 2025, 1:00 AM EST - 2 months ago

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)

Nov 10, 2025, 1:51 PM EST - 3 months ago

Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 6, 2025, 9:15 AM EST - 3 months ago

Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema

Nov 4, 2025, 3:15 PM EST - 3 months ago

Top Biotech Stocks Riding The Rally

CTMX GRAL GRFS

Nov 3, 2025, 9:31 AM EST - 3 months ago

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Oct 30, 2025, 8:00 AM EDT - 3 months ago

4 Best Value And Growth Stocks (Yes, They Can Coexist)

BAM CCSI GARP GRFS HRTG

Oct 30, 2025, 7:30 AM EDT - 3 months ago

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

Oct 28, 2025, 5:51 PM EDT - 3 months ago

Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio

Oct 28, 2025, 2:44 PM EDT - 3 months ago

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Oct 28, 2025, 11:41 AM EDT - 3 months ago

Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 8:02 AM EDT - 3 months ago

Incyte boosts annual sales forecast of blood cancer drug after strong quarter

Oct 28, 2025, 7:00 AM EDT - 3 months ago

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 27, 2025, 7:30 AM EDT - 3 months ago

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

Oct 25, 2025, 7:55 PM EDT - 3 months ago

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Night_Owl_Biotech Feb. 4 at 12:49 AM

0 · Reply

SuperGreenToday Feb. 3 at 11:13 PM

0 · Reply

SuperGreenToday Jan. 28 at 7:41 PM

0 · Reply

stinkroach Jan. 27 at 3:27 PM

$INCY

1 · Reply

JuggernautRaider Jan. 27 at 2:53 PM

0 · Reply

AdamURAtoFookingNeptune Jan. 23 at 7:52 PM

$EXEL $INCY small trims here

0 · Reply

ProfitFocus_34 Jan. 20 at 4:45 PM

$INCY midcap biotech steady accumulation if data cle

0 · Reply

notreload_ai Jan. 20 at 12:45 PM

Wells Fargo cut $INCY to Equal Weight and lowered its price target to $107. The bank says most upside is already priced in, with no big near-term catalysts, so the stock may trade sideways for now.

0 · Reply

JuggernautRaider Jan. 20 at 2:18 AM

2 · Reply

JuggernautRaider Jan. 19 at 10:21 PM

2 · Reply

Night_Owl_Biotech Jan. 19 at 4:11 PM

$SNDX v. the $XBI since 10/30/2025 We've noted countless times hereSNDX trades @ meaningfully lower multiples of analyst consensus revenue estimates versus its oncology focused peers (the discrepancy is even more apparent v. non-oncology). SNDX gross profit margin has been ~96% which is ultra-competitive v peers. If comm'l-stage bios like SNDX are worth some multiple &/or NPV of projected sales then... WTF is $INCY waiting for? Now that SNDX has reported Q425 sales, what could drive SNDX higher (since SNDX did not disclose imminent CRC data is forthcoming)? Will SNDX trade consistent with the XBI? How do SNDX bulls read the graph, especially the last week since rleasing Q425 sales? SNDX should report Q425 results @ the end of February which will likely include FY26 guidance...so 5-6 weeks $KURA will likely also provide preliminary FY26 guidance around the same time. Risk? This is not investment advice. We have no idea how any stock or market index will trade in the future. @JuggernautRaider

0 · Reply

Nomorelies Jan. 17 at 2:01 PM

$INCY Is this one a buyout target?

0 · Reply

JuggernautRaider Jan. 16 at 4:27 PM

Happy to. IQVIA & Symphony & Komodo are the three pharma industry leaders in sales (demand) data. biopharma data in the US is TERRIBLE given the market structure, number of different payers, et al. Often when a product is launched - particularly oral products like $TNXP Tonmya, $INCY Jakafi, $KPTI Xpovio, and even some infusion products like $JAZZ ’s Zepzelca they will block the distributors from selling the data. Usually 10-30% is not captured, but up to 60-95% can be if the pharma company only uses a few distributors & specialty pharamcies. Now this is demand or sales data - for claims data, which shows much more information (with the patient data hidden). However I doubt Tonix is doing that as it can be expensive (you have to pay them to do this - they know how valuable the data is to stock analyst & competitors). I’m hopeful we’ll see the first quarter of demand data from Tonmya soon - which will be its first month (during the holidays!) 😬 Almost to 10K shares long 💎 💪

3 · Reply

JuggernautRaider Jan. 16 at 4:15 PM

$TNXP we should see Symphony Or Komodo sales data for Tonmya soon… assuming Tonix isn’t using contracts with ira distributors to block it like $JAZZ and $KPTI and $INCY do 📊 this is a little trade secret for you all 🤫 get these shares while they’re cheap, I’m buying more ☘️ GLBB 🚀

1 · Reply

BillionerOfKing Jan. 16 at 1:57 AM

$INCY Current Stock Price: $105.25 Contracts to trade: $105 INCY Jan 16 2026 Call Entry: $0.75 Exit: $1.06 ROI: 41% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BillionerOfKing Jan. 15 at 12:27 AM

$INCY Current Stock Price: $105.96 Contracts to trade: $105 INCY Jan 16 2026 Call Entry: $0.75 Exit: $1.48 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

IN0V8 Jan. 13 at 6:20 PM

$INCY Buying Opportunity TD Cowen raises target price to $128 from $101

0 · Reply

JFais Jan. 13 at 1:37 PM

$SNDX- JPM notes, what you waiting for $INCY?

1 · Reply

Night_Owl_Biotech Jan. 12 at 7:35 PM

$SNDX disclosed actual FY25 Niktimvo US product sales were $152MM. SNDX owns 50% of Niktimvo with $INCY Niktimvo's peer therapy Rezurock from Kadmon Holdings (approved Q321) was acquired by Sanofi for $1.9B in Q421 Kadmon provided Sanofi a financial forecast that we assume was used to determine Rezurock's M&A valuation. Kadmon projected $63MM in first full year Rezurock sales. Hence simple math shows Niktimvo outsold Rezurock's forecast by more than 2.4X If new drugs like Niktimvo & Rezurock are worth some multiple and/or NPV of projected sales, and Niktimvo has outsold Rezurock by more than 2.4X, does this mean Niktimvo's hypothetical M&A valuation is 2.4X more than Rezurock? If Niktimvo was acquired for the same multiple of first full year sales as Rezurock's projection, Niktimvo's M&A valuation would be $4.6B. Again, SNDX owns 50% of Niktimvo. This is not investment advice. We have no idea if Niktimvo is worth the same revenue multiple as Rezurock. Pushback? $XBI $IBB $NBI

1 · Reply

SuperGreenToday Jan. 12 at 1:20 PM

$INCY Share Price: $106.87 Contract Selected: Jun 18, 2026 $105 Calls Buy Zone: $9.09 – $11.23 Target Zone: $14.57 – $17.81 Potential Upside: 51% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Finanz Jan. 12 at 1:37 AM

$INCY https://www.medpagetoday.com/meetingcoverage/mgics/119372?xid=nl_mpt_DHE_2026-01-11&mh=b54a366dc9d5338660d3e3884c1cd72d&zdee=gAAAAABm4vF5z62JTXRnKqmnKa-Tb9iwnMV8Wu3PD2SgF9iuoyPkQTeR7MSAj9PpC8n-a2DNApXBV5J8KYd1qOtizEJHnsaa7N5CZpcz_sxNsIs0zkHqb6o%3D&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Evening%20-%20Randomized%202026-01-11&utm_term=NL_Daily_DHE_dual-gmail-definition

0 · Reply

Night_Owl_Biotech Jan. 11 at 5:35 PM

$SNDX valuation as a multiple of cumulative 10-year projected revenues versus 9 peer comm'l-stage M&A transactions. Note SNDX projected 10-year revenues are, more or less, consistent with the average projected revenues of the peer group The peers were acquired for, on average, a 0.35X multiple of their cumulative 10-year projected revenues. SNDX trades @ 0.16X 10-year analyst projections. If anything, our model is conservative because the model uses FY25 as year 1 where, in theory, FY26 is the 1st year from today consistent with peers SWTX was acquired at the lowest multiples of the 9 peers. Most investors were disappointed with SWTX's M&A valuation. Recall SWTX traded as high as $60 per share when the rumor was disclosed & were acquired for $47. Our simple point is the average peer multiples would be more compelling v. SNDX if SWTX was excluded. We believe $INCY is the most likely SNDX acquisition candidate (see our previous post for why). This is not investment advice. $XBI $IBB $NBI

0 · Reply

Market Cap	19.65B
Revenue (ttm)	4.24B
Net Income (ttm)	32.61M
EPS (ttm)	N/A
PE Ratio	19.00
Forward PE	15.18
Profit Margin	0.77%
Debt to Equity Ratio	0.00

Volume	1,552,500
Avg Vol	2,032,930
Day's Range	N/A - N/A
Shares Out	196.32M
Stochastic %K	53%
Beta	0.82
Analysts	Sell
Price Target	$102.95